Home
Leadership
Science
Data
Media
- News
- Videos
Partners
Contact

Password Reset

Email Address

Search for:

About Us

SIWA’s 318H monoclonal antibody targets a biomarker on cancer cells, senescent cells, and microbially-infected cells. Our initial focus is on gastrointestinal and related diseases that are eligible for FDA Fast-tracking. We expect to file our first IND in late 2021 jointly with a major institution in pancreatic cancer/cachexia. ***

Recent News

Listen to Ashley Jensen discuss SIWA’s antibody at AACR’s Virtual Conference!
Listen to Lewis Gruber speak at the 2021 Metabestiy conference
Listen to our founder and CEO, Lewis Gruber discuss SIWA and 318H!

JOIN OUR MAILING LIST

Navigation

Home
Leadership
Science
Data
Media
- News
- Videos
Partners
Contact